Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Vomiting - why so common in kids?

Most kids vomit easily and often copiously and frequently. This is a global phenomenon most parents have resigned themselves to. Researchers have now tried to understand why kids vomit so commonly and if there is actually any reason for parents to panic. An article by Erin Blakemore for NPR looks to answer the question.

11 Sep 2018

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence.

7 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

UAMS’ multi-disciplinary structure offers best maternal and fetal care

Charlotte and Emelia Dubs are just starting to toddle around their world. The 1-year-old twin girls from Conway spend their days exploring, laughing, blowing kisses and keeping their parents, Kenzie Butcher-Dubs and Morgan Dubs, on their toes.

6 Sep 2018

UQ drug expert supports current medicinal cannabis policies in Australia

Cannabis-based medicines should only be used under medical supervision until clinical studies have assessed their safety and efficacy, a University of Queensland drug expert has cautioned.

5 Sep 2018

Areas with high density of alcohol outlets have more hospital admission rates

Areas with a high density of alcohol outlets have higher drink-related hospital admission rates, a new study from the University of Sheffield has found.

20 Aug 2018

FDA grants approval for first generic version of epinephrine auto-injector

The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds.

16 Aug 2018

FDA expands approval of Vertex' cystic fibrosis medicine to treat children aged 12 to <24 months

Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

16 Aug 2018

FDA approves first vaginal ring contraceptive that can be used for one year

The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

10 Aug 2018

FDA approves potassium chloride oral solution as first generic drug to receive CGT designation

The U.S. Food and Drug Administration today approved several strengths of potassium chloride oral solution as the first generic drugs to receive a Competitive Generic Therapy designation.

9 Aug 2018

Women having heart attacks experience longer wait time for cardiac intervention

A recent study shows women having heart attacks experience higher than 30% longer wait time from the onset of symptoms to hospital arrival than men and a higher than 20% longer time from hospital arrival to cardiac intervention compared to men.

1 Aug 2018

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

FDA approves first therapy for patients with rare tumors of the adrenal gland

The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy.

31 Jul 2018

New device uses single drop of blood to diagnose mild traumatic brain injury

Every year in Europe, three million people are admitted into hospitals for suspected mild traumatic brain injury cases. Yet 90% of these patients will be able to return home safely, as no trauma has been detected.

30 Jul 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

FDA grants approval for first breast cancer drug through 'Real-Time Oncology Review'

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

19 Jul 2018